Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa
- PMID: 24923339
- DOI: 10.2174/1871527313666140612114838
Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa
Abstract
Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
Similar articles
-
The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors.Psychopharmacology (Berl). 2011 Feb;213(2-3):465-73. doi: 10.1007/s00213-010-2036-z. Epub 2010 Oct 14. Psychopharmacology (Berl). 2011. PMID: 20945065
-
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.Braz J Psychiatry. 2012 Jun;34 Suppl 1:S104-10. doi: 10.1590/s1516-44462012000500008. Braz J Psychiatry. 2012. PMID: 22729452 Review. English, Portuguese.
-
Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action.Metab Brain Dis. 2021 Apr;36(4):639-652. doi: 10.1007/s11011-020-00667-3. Epub 2021 Jan 19. Metab Brain Dis. 2021. PMID: 33464458
-
Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors.Behav Brain Res. 2016 Apr 15;303:218-27. doi: 10.1016/j.bbr.2016.01.033. Epub 2016 Jan 20. Behav Brain Res. 2016. PMID: 26801828
-
Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.Biomed Res Int. 2018 Dec 4;2018:1691428. doi: 10.1155/2018/1691428. eCollection 2018. Biomed Res Int. 2018. PMID: 30627539 Free PMC article. Review.
Cited by
-
The neuropharmacology of cannabinoid receptor ligands in central signaling pathways.Eur J Neurosci. 2022 Feb;55(4):909-921. doi: 10.1111/ejn.14982. Epub 2020 Dec 5. Eur J Neurosci. 2022. PMID: 32974975 Free PMC article. Review.
-
A Comparative In Vitro Study of the Neuroprotective Effect Induced by Cannabidiol, Cannabigerol, and Their Respective Acid Forms: Relevance of the 5-HT1A Receptors.Neurotox Res. 2021 Apr;39(2):335-348. doi: 10.1007/s12640-020-00277-y. Epub 2020 Sep 4. Neurotox Res. 2021. PMID: 32886342
-
Cannabidiol activation of vagal afferent neurons requires TRPA1.J Neurophysiol. 2020 Nov 1;124(5):1388-1398. doi: 10.1152/jn.00128.2020. Epub 2020 Sep 23. J Neurophysiol. 2020. PMID: 32965166 Free PMC article.
-
The Endocannabinoids-Microbiota Partnership in Gut-Brain Axis Homeostasis: Implications for Autism Spectrum Disorders.Front Pharmacol. 2022 Jun 3;13:869606. doi: 10.3389/fphar.2022.869606. eCollection 2022. Front Pharmacol. 2022. PMID: 35721203 Free PMC article. Review.
-
Assessing Cannabis Use Disorder in Medical Cannabis Patients: Interim Analyses from an Observational, Longitudinal Study.Cannabis. 2021 Oct 1;4(2):47-59. doi: 10.26828/cannabis/2021.02.004. eCollection 2021. Cannabis. 2021. PMID: 37287530 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous